Physician profile
Jason D Moellinger
NPI 1629165535
$5,136.60
in general payments reported to CMS, 2019-2025
42 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $531 · 2021: $354 · 2022: $621 · 2023: $610 · 2024: $2,060 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.88 |
| Travel and Lodging | $966.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,632.44 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $1,108.34 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $421.88 | 2019-2025 | Xtandi |
| Urovant Sciences INC | $286.52 | 2021-2022 | |
| Abbvie INC. | $153.31 | 2019-2022 | |
| Pfizer INC. | $152.89 | 2020-2024 | |
| Integra Lifesciences Corporation | $148.52 | 2020 | |
| Allergan, INC. | $105.75 | 2020 | |
| Rochester Medical Corporation | $77.52 | 2021 | |
| Immunitybio, INC. | $59.77 | 2025 | |
| Ferring Pharmaceuticals INC. | $56.38 | 2025 | Adstiladrin |
| Coloplast Corp | $55.21 | 2019-2023 | Speedicath |
| Cook Medical LLC | $54.03 | 2025 | Cook |
| Myovant Sciences INC. | $53.54 | 2022 | |
| Tolmar, INC. | $50.97 | 2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Moellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.